A therapeutic vaccine targeting human papillomavirus type 16 (HPV16) induced regression in high-grade precancerous cervical lesions, according to the results from a phase II clinical trial.
An investigational therapeutic vaccine showed clinical effectiveness in patients with human papillomavirus (HPV)16-positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback